arrow_back Back to App

Equal Costs for Cancer Drugs: Oral and Intravenous

New rules aim to ensure that insurance plans treat oral cancer medications the same as intravenous ones regarding costs. This means citizens should not pay more for oral anticancer drugs, potentially reducing their treatment expenses. The law is set to take effect from January 1, 2024.
Key points
Insurers cannot charge more for oral cancer drugs than for intravenous ones.
Prohibits increasing cancer treatment costs or reclassifying benefits to raise patient expenses.
The act does not require replacing intravenous drugs with oral ones, nor does it prevent insurers from requiring prior authorization for treatment.
The government will study the impact of these changes on patient out-of-pocket costs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6301
Sponsor: Rep. Grothman, Glenn [R-WI-6]
Process start date: 2023-11-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Cancer Drug Parity Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6301.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-11-08.

What are the main provisions?

Key points include:

  • Insurers cannot charge more for oral cancer drugs than for intravenous ones.
  • Prohibits increasing cancer treatment costs or reclassifying benefits to raise patient expenses.
  • The act does not require replacing intravenous drugs with oral ones, nor does it prevent insurers from requiring prior authorization for treatment.
  • The government will study the impact of these changes on patient out-of-pocket costs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Grothman, Glenn [R-WI-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Education and the Workforce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health